Hengbang Wang

Discovery of 4-((3′<i>R</i>,4′<i>S</i>,5′<i>R</i>)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Angelo Aguilar, Jianfeng Lü, Liu Liu et al. · Journal of Medicinal Chemistry · 2017 · 203 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Qian Jiang, Zongru Li, Ya‐Zhen Qin et al. · Journal of Hematology & Oncology · 2022 · 99 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy

Jing Deng, Aneel Paulus, Douglas D. Fang et al. · Clinical Cancer Research · 2022 · 54 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Sikander Ailawadhi, Zi Chen, Bo Huang et al. · Clinical Cancer Research · 2023 · 38 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.

Drew Rasco, Nehal J. Lakhani, Yufeng Li et al. · Journal of Clinical Oncology · 2019 · 27 citations

Medicine, Oncology, Pharmacology +17